BioStock: Aqilion and Merck sever ties

Aqilion announced the termination of the licensing and collaboration agreement with Merck for the joint development of the TAK1 programme taking aim at chronic inflammation. The decision follows data generated during the partnership, which indicated a shift in the risk-benefit profile for the targeted indications. BioStock reached out to Aqilion’s CEO Sarah Fredriksson for a comment.

Read the article at biostock.se:

Aqilion and Merck sever ties - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/